

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM338844

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Concordia Healthcare Corp.		04/21/2015	CORPORATION: CANADA
Concordia Pharmaceuticals Inc.		04/21/2015	CORPORATION: BARBADOS
Concordia Laboratories Inc.		04/21/2015	CORPORATION: BARBADOS
Pinnacle Biologics, Inc.		04/21/2015	CORPORATION: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	Royal Bank of Canada
<b>Street Address:</b>	20 King Street West, 4th Floor
<b>City:</b>	Toronto
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	M5H 1C4
<b>Entity Type:</b>	Bank: CANADA

## PROPERTY NUMBERS Total: 17

Property Type	Number	Word Mark
Registration Number:	1949186	NILANDRON
Registration Number:	1470405	PLAQUENIL
Registration Number:	0712043	PLAQUENIL
Registration Number:	0562377	PLAQUENIL
Registration Number:	2679884	UROXATRAL
Registration Number:	0667320	KAYEXALATE
Registration Number:	4158771	DUTOPROL
Registration Number:	0785081	DYRENIUM
Registration Number:	0548626	DIBENZYLINE
Registration Number:	4440904	TWISTVIAL
Registration Number:	4365005	KAPVAY
Registration Number:	2185127	ORAPRED
Registration Number:	3248392	ORAPRED ODT
Registration Number:	0338733	DONNATAL
Registration Number:	1367281	PHOTOFRIN
Serial Number:	85728543	CENTRIGUIDE

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	2055737	OPTIGUIDE

**CORRESPONDENCE DATA**

**Fax Number:** 2123037064

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212.318.6824

**Email:** christinedionne@paulhastings.com

**Correspondent Name:** Christine Dionne c/o Paul Hastings LLP

**Address Line 1:** 75 East 55th Street

**Address Line 4:** New York, NEW YORK 10022

**ATTORNEY DOCKET NUMBER:** 78436.00172 (TM)

**NAME OF SUBMITTER:** Christine Dionne

**SIGNATURE:** /Christine Dionne/

**DATE SIGNED:** 04/21/2015

**Total Attachments: 15**

source=Concordia Intellectual Property Security Agreement Executed#page1.tif  
source=Concordia Intellectual Property Security Agreement Executed#page2.tif  
source=Concordia Intellectual Property Security Agreement Executed#page3.tif  
source=Concordia Intellectual Property Security Agreement Executed#page4.tif  
source=Concordia Intellectual Property Security Agreement Executed#page5.tif  
source=Concordia Intellectual Property Security Agreement Executed#page6.tif  
source=Concordia Intellectual Property Security Agreement Executed#page7.tif  
source=Concordia Intellectual Property Security Agreement Executed#page8.tif  
source=Concordia Intellectual Property Security Agreement Executed#page9.tif  
source=Concordia Intellectual Property Security Agreement Executed#page10.tif  
source=Concordia Intellectual Property Security Agreement Executed#page11.tif  
source=Concordia Intellectual Property Security Agreement Executed#page12.tif  
source=Concordia Intellectual Property Security Agreement Executed#page13.tif  
source=Concordia Intellectual Property Security Agreement Executed#page14.tif  
source=Concordia Intellectual Property Security Agreement Executed#page15.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “**IP Security Agreement**”) dated April 21, 2015, is made by the persons listed on the signature pages hereof (collectively, the “**Grantors**”) in favor of Royal Bank of Canada, acting through one or more of its branches or any Affiliate thereof, as collateral agent (in such capacity and any successor in such capacity, the “**Collateral Agent**”) for the Secured Parties (as defined in the Credit Agreement referred to below). Capitalized terms used in this IP Security Agreement and not otherwise defined herein have the respective meanings assigned thereto in the Credit Agreement (as defined below).

WHEREAS, the Grantors have entered into that certain Credit and Guaranty Agreement, dated as of April 21, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), with Concordia Healthcare Corp., a corporation incorporated under the laws of the Province of Ontario (the “**Borrower**”), the other Credit Parties party thereto, Royal Bank of Canada, as the Administrative Agent and Collateral Agent and the Lenders party thereto from time to time;

WHEREAS, as a condition precedent to the making of Loans by the Lenders and the entry into Hedge Agreements and Cash Management Agreements by the Lender Counterparties from time to time, (i) each Grantor has executed and delivered that certain Pledge and Security Agreement, dated as of April 21, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), by and among the Grantors, the Administrative Agent and the Collateral Agent and (ii) the Canadian Domiciled Credit Parties have executed and delivered that certain Canadian Pledge and Security Agreement, dated as of April 21, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “**Canadian Security Agreement**”); and

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the United States Patent and Trademark Office and the United States Copyright Office;

WHEREAS, under the terms of the Canadian Security Agreement, the Canadian Domiciled Credit Parties have granted to the Collateral Agent, for the ratable benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Canadian Domiciled Credit Parties, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the Canadian Intellectual Property Office;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

SECTION 1. Grant of Security. Each Grantor hereby grants to the Collateral Agent for the ratable benefit of the Secured Parties a security interest in such Grantor’s right, title and interest in and to the following (collectively, the “**IP Collateral**”):

- (i) the patents and patent applications set forth in Schedule A hereto;
- (ii) the trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications or intent-to-use service mark applications filed pursuant to Section 1(b) of the

Lanham Act, to the extent that, the grant of a security interest therein would impair the validity or enforceability of, or render void or voidable or result in the cancellation of the applicable Grantor's right, title or interest therein or any trademark or service mark issues as a result of such application under applicable federal law), together with the goodwill symbolized thereby;

(iii) the copyright registrations and applications set forth in Schedule C hereto;

(iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing;

(v) any and all claims for damages and injunctive relief for past, present and future infringement of any of the foregoing; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing or arising from any of the foregoing.

SECTION 2. Security for Obligations. The grant of a security interest in the IP Collateral by each Grantor under this IP Security Agreement secures the payment of all Obligations of such Grantor now or hereafter existing under or in respect of the Credit Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

SECTION 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement.

SECTION 4. Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement and the Canadian Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. Each Canadian Domiciled Credit Party does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the IP Collateral are more fully set forth in the Canadian Security Agreement.

SECTION 6. Governing Law. This IP Security Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

**[Signatures pages to follow]**

IN WITNESS WHEREOF, each Grantor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

**CONCORDIA HEALTHCARE CORP.,**  
as Grantor

By: \_\_\_\_\_  
Name: *Mark Thompson*  
Title: *President + CEO*

**CONCORDIA PHARMACEUTICALS, INC.,**  
as Grantor

By: \_\_\_\_\_  
Name:  
Title:

**CONCORDIA LABORATORIES INC.,**  
as Grantor

By: \_\_\_\_\_  
Name:  
Title:

**PINNACLE BIOLOGICS, INC.,**  
as Grantor

By: \_\_\_\_\_  
Name: *Mark Thompson*  
Title: *CEO*

[Signature Page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, each Grantor has caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

**CONCORDIA HEALTHCARE CORP.,**

as Grantor

By: \_\_\_\_\_  
Name:  
Title:

**CONCORDIA PHARMACEUTICALS, INC.,**

as Grantor

By: \_\_\_\_\_  
Name: Andrew K. Ferrera  
Title: Director

**CONCORDIA LABORATORIES INC.,**

as Grantor

By: \_\_\_\_\_  
Name: Andrew J. Ferrera  
Title: Director

**PINNACLE BIOLOGICS, INC.,**

as Grantor

By: \_\_\_\_\_  
Name:  
Title:

[Signature Page to Intellectual Property Security Agreement]

### Patents and Patent Applications

a. Concordia Pharmaceuticals Inc.

Country	Patent Name / Application	Application Filing Date/ Date Issued	Application Number/ Registration Number	Registered Owner	Actual Owner
United States	Sustained release compositions of alfuzosin hydrochloride	12/31/1996	US 5,589,190	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	Pleasant-tasting aqueous liquid composition of a bitter-tasting drug	6/9/1998	US 5,763,449	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.
Mexico	Pleasant-tasting aqueous liquid composition of a bitter-tasting drug	3/23/2004	MX 219490	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.

b. Concordia Laboratories Inc.

Country	Patent Name / Application	Application Filing Date/ Date Issued	Application Number/ Registration Number	Registered Owner	Actual Owner
United States	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofrin	November 29, 2012	13/689,490	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Canada	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofrin	January 7, 2013	2,871,849	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Europe	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofrin	January 7, 2013	13 838060.5	Concordia Laboratories Inc.	Concordia Laboratories Inc.

Country	Patent Name / Application	Application Filing Date/ Date Issued	Application Number/ Registration Number	Registered Owner	Actual Owner
Korea	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofrin	January 7, 2013	10-2014-7036759	Concordia Laboratories Inc.	Concordia Laboratories Inc.
China	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofrin	January 7, 2013	201380028833.2	Concordia Laboratories Inc.	Concordia Laboratories Inc.
India	In Vitro Potency Assay for Photofrin	June 28, 2013	412/CHENP/2013	Pinnacle Biologics, Inc.	Concordia Laboratories Inc.



### Trademark and Service Mark Registrations and Applications

a. Concordia Pharmaceuticals Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
United States	NILANDRON	74/646,174	1949186	January 16, 1996	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	73/662,985	1470405	December 29, 1987	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	72/102433	712043	March 7, 1961	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	71/618068	562377	July 29, 1952	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	UROXATRAL	76/233890	2679884	January 28, 2003	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	KAYEXALATE	72/044216	0667320	September 23, 1958	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	DUTOPROL	85/266138	4158771	June 12, 2012	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	DYRENIUM	72/193818	785081	February 16, 1965	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	DIBENZYLIN	71/586367	548626	September 25, 1951	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	TWISTVIAL	85/580265	4440904	November 26, 2013	Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.
United States	KAPVAY	77/864,611	4,365,005	July 9, 2013	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.

Schedule B

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
United States	ORAPRED	75/284,813	2,185,127	August 25, 1998	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.
United States	ORAPRED ODT	78/642,154	3,248,392	May 29, 2007	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.
Korea		40-2012-0029768	40-0959504	March 20, 2013	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.
United States	DONNATAL	71/377,644	338733	September 15, 1936	Concordia Pharmaceuticals Inc.	Concordia Pharmaceuticals Inc.
Austria	DONNATAL	48143	48143	Jun 15, 1962	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Canada	DONNATAL	184,746	20197	Jul 28, 1944	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
EU	DONNATAL	008515769	008515769	Mar 22, 2010	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
France	DONNATAL	71780	1,300,540	Feb 26, 1985	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Germany	DONNATAL	29 593/5 Wz	920669	Jul 19, 1974	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Italy	DONNATAL	41462C/85	741,001	Oct 6, 1986	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Mexico	DONNATAL (stylized)	1224263	1,278,961	Apr 12, 2012	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Mexico	DONNATAL (stylized)	33197	53,847	Apr 21, 1947	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
Puerto Rico	KAYEXALATE	73532			Covis Pharma S.à r.l.	Concordia Pharmaceuticals Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
Sweden	DONNATAL	9310657	259219	Jun 23, 1994	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.
United Kingdom	DONNATAL	779813	779,813	Jul 16, 1958	PBM Pharmaceuticals, Inc.	Concordia Pharmaceuticals Inc.

b. Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
United States	PHOTOFRIN	73-437,839	1,367,281	October 29, 1985	Concordia Laboratories Inc.	Concordia Laboratories Inc.
United States	CENTRIGUIDE	85-728,543			Concordia Laboratories Inc.	Concordia Laboratories Inc.
United States	OPTIGUIDE	74-502,189	2055737	January 22, 1997	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Argentina	PHOTOFRIN	2 538 722	2 077 841	2006-04-05	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Australia	PHOTOFRIN	516674	516674	1989-08-09	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Austria	PHOTOFRIN	378089	127 506	1989-10-04	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Barbados	PHOTOFRIN	81/13390	81/13390	2001-12-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Belize	PHOTOFRIN	2767.04	2767.04	2005-02-28	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Benelux	PHOTOFRIN	733026	465458	1989-08-14	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Bolivia	PHOTOFRIN	SM-1326-2005	103766	2006-05-30	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
Brazil	PHOTOFRIN	816128774	816128774	1992-10-06	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Canada	PHOTOFRIN	552103	347707	1988-11-10	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Chile	PHOTOFRIN	645.165	708.925	2005-01-03	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
China	PHOTOFRIN	9001392	258625	1986-08-10	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Colombia	PHOTOFRIN	06033270	325488	2006-11-20	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Costa Rica	PHOTOFRIN	78482	78482	1992-02-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Croatia	PHOTOFRIN	2931800	931800	1993-05-19	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Cuba	PHOTOFRIN	2005-0228	2005-0228	2006-06-27	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Denmark	PHOTOFRIN	05897/1989	08068/1990	1990-12-14	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Dominican Republic	PHOTOFRIN	2005-25248	148631	2005-07-15	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Ecuador	PHOTOFRIN	156142-05	3981-05	2005-12-19	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Finland	PHOTOFRIN	---	113364	2001-08-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
France	PHOTOFRIN	925988	1464366	1988-10-05	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Germany	PHOTOFRIN	v 57490	DD646 804	1990-01-08	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Germany	PHOTOFRIN	Q1282/5W Z	1175616	1991-04-30	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Greece	PHOTOFRIN	95117	95117	1992-09-17	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Guatemala	PHOTOFRIN	326691	67993	1992-10-06	Pinnacle Biologics B.V.	Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
Honduras	PHOTOFRIN	55.591	55.591	1992-06-12	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Hong Kong	PHOTOFRIN	6887/1989	B05584/1993	1989-08-29	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Hungary	PHOTOFRIN	M8902001	129 044	1990-04-10	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Iceland	PHOTOFRIN	1878/2001	1110/2001	2001-12-03	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
India	PHOTOFRIN	521429	---	---	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Ireland	PHOTOFRIN	141423	141423	1989-08-09	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Israel	PHOTOFRIN	73318	73318	1993-04-26	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Italy	PHOTOFRIN	RM98C005874	526 422	1990-04-18	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Korea	PHOTOFRIN	1989-0020474	40-0203831	1990-08-27	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Latvia	PHOTOFRIN	93 8406	33462	1996-06-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Lithuania	PHOTOFRIN	13243	24181	1997-01-23	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Macedonia	PHOTOFRIN	206/93	498	1995-07-06	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Malaysia	PHOTOFRIN	89004910	89004910	1989-05-15	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Mexico	PHOTOFRIN	118215	408310	1992-03-19	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Montenegro (formerly part of Serbia)	PHOTOFRIN	Z851/89	34753	1990-07-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
New Zealand	PHOTOFRIN	195314	195314	1992-03-26	Concordia Laboratories Inc.	Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
Nicaragua	PHOTOFRIN	21526CC	21526CC	1992-06-04	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Norway	PHOTOFRIN	1989 3963	145058	1991-05-15	Concordia Laboratories Inc.	Concordia Laboratories Inc.
OHIM(EU)	PHOTOFRIN	002062081	002062081	2002-03-14	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Pakistan	PHOTOFRIN	---	103666	1989-08-27	QLT Inc.	Concordia Laboratories Inc.
Panama	PHOTOFRIN	58051	58051	1992-11-11	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Paraguay	PHOTOFRIN	21123	276274	2005-03-16	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Peru	PHOTOFRIN	267549	115024	2006-05-05	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Poland	PHOTOFRIN	88419	65815	1991-03-11	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Portugal	PHOTOFRIN	258284	258284	1993-05-10	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Puerto Rico	PHOTOFRIN	---	31084	1992-09-16	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Russia	PHOTOFRIN	114 833	88599	1999-04-16	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Saudi Arabia	PHOTOFRIN	9894	215/61	1990-03-20	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
Serbia (formerly Yugoslavia)	PHOTOFRIN	Z851/89	34753	1990-07-20	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Singapore	PHOTOFRIN	T89/05330H	T89/05330H	1989-08-14	Pinnacle Biologics B.V.	Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
Slovenia	PHOTOFRIN	9370417	9370417	1994-09-05	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
South Africa	PHOTOFRIN	1989/07 110	89/07 110	1989-08-09	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Spain	PHOTOFRIN	1255299	1255299	1995-02-10	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Sweden	PHOTOFRIN	89-07 422	224 910	1991-07-05	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Switzerland	PHOTOFRIN	6045	374 964	1989-08-10	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Taiwan	PHOTOFRIN	90048432	01014334	2002-09-16	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Turkey	PHOTOFRIN	---	115726	1989-08-22	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Ukraine	PHOTOFRIN	93 115 356	9260	1997-12-25	Axcan Pharma PDT Inc.	Concordia Laboratories Inc.
United Kingdom	PHOTOFRIN	1257851	1257851	1986-01-10	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Uruguay	PHOTOFRIN	347549	347.549	2004-03-05	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Venezuela	PHOTOFRIN	6945-1991	163204	1994-07-18	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
Vietnam	PHOTOFRIN	11 332	9559	1993-11-19	Pinnacle Biologics B.V.	Concordia Laboratories Inc.
France	OPTIGUIDE	---	95569743	1995-04-28	Concordia Laboratories Inc.	Concordia Laboratories Inc.
Ireland	PHOTOBARR	2003/00500	226875	2003-03-20	Concordia Laboratories Inc.	Concordia Laboratories Inc.

Country	Trademark	Application no.	Registration No.	Date of Registration	Registered Owner	Actual Owner
OHIM (EU)	PHOTOBARR	003340651	003340651	2005-05-23	Concordia Laboratories Inc.	Concordia Laboratories Inc.
WIPO	PHOTOBARR	811627	811627	2003-09-18	Pinnacle Biologics B.V.	Concordia Laboratories Inc.



**Copyright Registrations and Applications**

None.

Schedule C